Legend Biotech Corporation
LEGN
Hisse Senetlerindeki Sıralama
#4417
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Hisse Fiyatı
$19.08
Piyasa Değeri
$3.53B
Değişim (1 gün)
2.31%
Değişim (1 yıl)
-42.02%
Ülke
US
Ticaret Legend Biotech Corporation (LEGN)
Kategori
Healthcare
Legend Biotech Corporation (LEGN) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-56.27M
Legend Biotech Corporation şirketinin en son finansal raporlarına göre, mevcut kazancı $-56.27M'dir. 2023 yılında şirket $-520.12M kazanç elde etti, bu 2022 yılındaki $-445.72M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Legend Biotech Corporation için kazanç geçmişi 2017 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-56.27M | -64.41% |
| 2024 | $-158.13M | -69.60% |
| 2023 | $-520.12M | 16.69% |
| 2022 | $-445.72M | 9.46% |
| 2021 | $-407.20M | 32.08% |
| 2020 | $-308.29M | 142.14% |
| 2019 | $-127.32M | 7,778.65% |
| 2018 | $-1.62M | -111.68% |
| 2017 | $13.84M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -9,473.93% |
US
|
|
| $-3.09B | 5,385.85% |
US
|
|
| $-4.02B | 7,037.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,566.47% |
NL
|
